Parkin is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Parkin is an E3 ubiquitin ligase encoded by the [PRKN[/genes/[parkin[/genes/[parkin[/genes/[parkin--TEMP--/genes)--FIX-- gene (also known as PARK2) on chromosome 6q26. Parkin plays a critical role in mitochondrial quality control through mitophagy—the selective autophagy of damaged mitochondria[1]. Pathogenic mutations in PRKN are the most common cause of autosomal recessive young-onset Parkinson's disease, accounting for approximately 50% of familial cases and 10-15% of sporadic early-onset cases[2].
Parkin functions as a master regulator of mitochondrial homeostasis, tagging damaged mitochondria for elimination and coordinating their removal through the autophagy-lysosome pathway. This function is essential for neuronal survival, as dopaminergic neurons are particularly dependent on mitochondrial quality control due to their high metabolic demands and oxidative stress exposure.
¶ Domain Organization
Parkin contains multiple functional domains:
- N-terminal ubiquitin-like (Ubl) domain (1-76): Regulates Parkin activity and interactions
- RING0 domain (78-165): Unique to Parkin family, structural scaffold
- RING1 domain (212-286): First RING finger, E2 binding
- In-between-RING (IBR) domain (327-380): Intermediate domain
- RING2 domain (418-465): Second RING finger, contains catalytic cysteine (Cys431)
Parkin exists in an auto-inhibited conformation:
- Ubl domain blocks catalytic site
- RING0 restricts substrate access
- Activation requires phosphorylation (by PINK1) and conformational change
The crystal structures reveal that Parkin adopts a "closed" conformation in the inactive state. Upon activation, dramatic conformational rearrangements expose the catalytic RING2 domain.
The PINK1-Parkin pathway is the primary mechanism for mitochondrial quality control:
- PINK1 accumulation: On damaged mitochondria, PINK1 accumulates on the outer membrane
- Phosphorylation: PINK1 phosphorylates ubiquitin and Parkin's Ubl domain
- Parkin recruitment: Phospho-ubiquitin recruits Parkin to damaged mitochondria
- Ubiquitination: Active Parkin ubiquitinates mitochondrial outer membrane proteins
- Autophagy recognition: Ubiquitinated mitochondria are recognized by autophagic receptors (p62, OPTN, NDP52)
- Lysosomal degradation: Damaged mitochondria are delivered to lysosomes
Parkin regulates mitochondrial:
- Biogenesis: Through PGC-1α signaling
- Fission: Via ubiquitination of fission factors
- Fusion: Modulates fusion protein function
- Transport: Affects mitochondrial trafficking in neurons
Parkin ubiquitinates numerous substrates beyond mitophagy:
- Mitochondrial proteins: VDAC1, Mfn1/2, Miro1
- Pathogens: Bacterial and viral proteins
- Synaptic proteins: Ensures proper synaptic function
PRKN mutations cause PD through loss of function:
- Impaired mitophagy
- Accumulation of dysfunctional mitochondria
- Increased oxidative stress
- Progressive dopaminergic neuron death
Parkin deficiency leads to:
- Reduced ATP production
- Increased reactive oxygen species (ROS)
- Impaired calcium handling
- Enhanced apoptosis susceptibility
Dopaminergic neurons in the substantia nigra are particularly vulnerable due to:
- High metabolic demands
- Complex axonal architecture
- Reliance on mitochondrial quality control
| Mutation Type |
Examples |
Effect |
Frequency |
| Missense |
C431F, R42P, K161N |
Reduced catalytic activity |
Common |
| Nonsense |
Q34X, R245X |
Truncated protein |
Less common |
| Deletions |
Exon 3-4 deletions |
Null alleles |
Common |
| Multiplications |
Duplications |
Reduced function |
Rare |
Over 200 pathogenic mutations have been identified, spanning the entire gene.
- AAV-Parkin: Deliver functional PRKN gene to brain
- CRISPR editing: Correct mutations in situ
- Enhancement strategies: Increase endogenous expression
- Mitophagy inducers: Promote PINK1-Parkin pathway
- Mitochondrial stabilizers: Protect mitochondria from damage
- Antioxidants: Counteract oxidative stress
- Mitochondrial dynamics modulators: Restore fission/fusion balance
- Metabolic support: Enhance neuronal energy
- Anti-apoptotic agents: Prevent cell death
- Imaging: Dopamine transporter (DAT) PET
- CSF: Neurofilament light chain (NfL)
- Blood: Mitochondrial function assays
¶ Drug Candidates
| Drug/Approach |
Mechanism |
Stage |
Status |
| AAV-Parkin gene therapy |
Gene delivery |
Phase 1/2 |
Ongoing |
| Mitophagy inducers |
Pathway activation |
Discovery |
Preclinical |
| Small molecule activators |
Parkin activation |
Discovery |
Lead optimization |
| PINK1 activators |
Upstream activation |
Discovery |
Early stage |
- [PRKN Gene[/genes/[parkin[/genes/[parkin[/genes/[parkin--TEMP--/genes)--FIX--: Gene encoding Parkin
- [Parkinson's Disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--: Primary disease
- [PINK1[/entities/[pink1-protein[/entities/[pink1-protein[/entities/[pink1-protein--TEMP--/entities)--FIX--: Partner kinase
- [PINK1-Parkin Mitophagy Pathway[/mechanisms/[pink1-parkin-mitophagy-pathway[/mechanisms/[pink1-parkin-mitophagy-pathway[/mechanisms/[pink1-parkin-mitophagy-pathway--TEMP--/mechanisms)--FIX--: Pathway
- [Mitochondrial Dysfunction[/mechanisms/[mitochondrial-dysfunction-parkinsons[/mechanisms/[mitochondrial-dysfunction-parkinsons[/mechanisms/[mitochondrial-dysfunction-parkinsons--TEMP--/mechanisms)--FIX--: Disease mechanism
- [Dopaminergic Neurons[/cell-types/[dopaminergic-neurons[/cell-types/[dopaminergic-neurons[/cell-types/[dopaminergic-neurons--TEMP--/cell-types)--FIX--: Target cells
The study of Parkin has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [/diseases/parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--
- [/mechanisms/alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein--TEMP--/mechanisms)--FIX--
- [/mechanisms/app-processing[/mechanisms/[app-processing[/mechanisms/[app-processing[/mechanisms/[app-processing--TEMP--/mechanisms)--FIX--
- [/mechanisms/amyloid-aggregation[/mechanisms/[amyloid-aggregation[/mechanisms/[amyloid-aggregation[/mechanisms/[amyloid-aggregation--TEMP--/mechanisms)--FIX--
- [/mechanisms/mitochondrial-dysfunction-ad[/mechanisms/[mitochondrial-dysfunction-ad[/mechanisms/[mitochondrial-dysfunction-ad[/mechanisms/[mitochondrial-dysfunction-ad--TEMP--/mechanisms)--FIX--
- Pickrell AM, Youle RJ. (2015). "The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease". Neuron 85(2):257-273. PMID:25618789
- Lücker K, et al. (2020). "Parkin mutations and phenotype". J Parkinsons Dis 10(3):939-949. PMID:32444550
- McWilliams TG, et al. (2018). "Basal mitophagy occurs independently of PINK1 in mouse tissues". Mol Cell 70(2):296-310. PMID:29626934
- Kazlauskaite A, et al. (2014). "Parkin is activated by PINK1-dependent phosphorylation of ubiquitin". Nat Chem Biol 10(7):508-515. PMID:24837326
- Koyano F, et al. (2014). "Ubiquitin is phosphorylated by PINK1 to activate parkin". Nature 510(7503):162-166. PMID:24784582
¶ Diagnosis and Genetic Testing
Genetic testing for PRKN mutations is recommended for:
- Early-onset PD (<50 years) with family history
- Autosomal recessive inheritance pattern
- Dystonia as presenting symptom
- Consanguineous families
Testing involves sequencing of all exons and deletion/duplication analysis.
Patients with PRKN mutations typically present with:
- Bilateral symmetric parkinsonism
- Early onset (typically before age 40)
- Good levodopa response
- Sleep benefit (improvement in morning)
- Dystonia as early feature
Disease progression in PRKN-related PD is generally slower than sporadic PD:
- Longer disease duration before severe disability
- Less cognitive decline in early stages
- Motor fluctuations and dyskinesias may develop earlier